LexDanaLexDanabeta
Inventor

Odile Esther Levy

Inventor
San Diego, CA, US

Overview

29→
Patents
1997–2017
Patent span
Human necessities
Primary field (CPC A)

Patents· 29 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary
A61KPreparations for medical, dental or toiletry purposes33%
C07KPeptides31%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations27%
C07CAcyclic or carbocyclic compounds4%
C07DHeterocyclic compounds2%
Y02PClimate change mitigation technologies in the production or processing of goods1%
Y10TTechnical subjects covered by former us classification1%
PatentTitleYear
9,593,154'Engineered polypeptides having enhanced duration of action'20179,453,063'Hybrid polypeptides with selectable properties'20169,133,260'GIP analog and hybrid polypeptides with selectable properties'20158,906,849'Pancreatic polypeptide family motifs, polypeptides and methods comprising the same'20148,895,498'GIP and exendin hybrid polypeptides'20148,759,295'Peptide-peptidase inhibitor conjugates and methods of using same'20148,697,647'Hybrid polypeptides with selectable properties'20148,603,969'Pancreatic polypeptide family motifs and polypeptides comprising the same'20138,598,314'Peptide-peptidase-inhibitor conjugates and methods of making and using same'20138,497,240'DPP-IV resistant GIP hybrid polypeptides with selectable properties'20138,426,361'Pancreatic polypeptide family motifs, polypeptides and methods comprising the same'20138,404,637'GIP analog and hybrid polypeptides with selectable properties'20138,263,545'GIP analog and hybrid polypeptides with selectable properties'2012RE043298'Peptides as NS3-serine protease inhibitors of hepatitis C virus'20128,076,288'Hybrid polypeptides having glucose lowering activity'20117,723,471'Pancreatic polypeptide family motifs, polypeptides and methods comprising the same'20107,595,299'Peptides as NS3-serine protease inhibitors of hepatitis C virus'20097,262,211'Aromatic heterocyclic non-covalent inhibitors of urokinase and blood vessel formation'20077,244,721'Peptides as NS3-serine protease inhibitors of hepatitis C virus'20077,169,760'Peptides as NS3-serine protease inhibitors of hepatitis C virus'20077,019,019'Matriptase inhibitors and methods of use'20067,012,066'Peptides as NS3-serine protease inhibitors of hepatitis C virus'20066,800,434'Peptides as NS3-serine protease inhibitors of hepatitis C virus'20046,586,405'Non-covalent inhibitors of urokinase and blood vessel formation'20036,376,649'Methods for the synthesis of - hydroxy--amino acid and amide derivatives'20025,932,733'3-amino-2-oxo-1-piperidineacetic derivatives containing an arginine mimic as enzyme inhibitors'19995,883,107'Arginine mimic derivatives as enzyme inhibitors'19995,714,499'3-amino-2-oxo-1-piperidineacetic derivatives containing an arginine mimic as enzyme inhibitors'19985,637,599'Arginine mimic derivatives as enzyme inhibitors'1997

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1997–2017Based in San Diego, CA, US· patent location history
2011–2014Patents assigned to LEVY ODILE ESTHER (11)· patent assignee history
2011–2014Patents assigned to D SOUZA LAWRENCE J (10)· patent assignee history
2011–2014Patents assigned to GHOSH SOUMITRA S (9)· patent assignee history
2013–2017Patents assigned to AMYLIN PHARMACEUTICALS LLC (11)· patent assignee history
2013–2017Patents assigned to ASTRAZENECA PHARMACEUTICALS LP (10)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
AMYLIN PHARMACEUTICALS LLC112013–2017
LEVY ODILE ESTHERself112011–2014
ASTRAZENECA PHARMACEUTICALS LP102013–2017
D SOUZA LAWRENCE J102011–2014
GHOSH SOUMITRA S92011–2014
Locations
LocationPatentsSpan
San Diego, California, US291997–2017